tiprankstipranks
Advertisement
Advertisement

HK:2575 Stock Latest News

Xuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products
Company AnnouncementsXuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products
5h ago
2575
Xuanzhu Biopharmaceutical Sets Board Meeting to Approve 2026 Interim Results
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Sets Board Meeting to Approve 2026 Interim Results
13d ago
2575
Xuanzhu Biopharm ordered to pay RMB9.33 million in arbitration over generic drug deal
PremiumCompany Announcements
Xuanzhu Biopharm ordered to pay RMB9.33 million in arbitration over generic drug deal
1M ago
2575
Xuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
PremiumCompany Announcements
Xuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
2M ago
2575
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori Eradication
PremiumCompany Announcements
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori Eradication
2M ago
2575
Xuanzhu Biopharmaceutical Shareholders Approve AGM Resolutions and Governance Overhaul
PremiumCompany AnnouncementsXuanzhu Biopharmaceutical Shareholders Approve AGM Resolutions and Governance Overhaul
2M ago
2575
Xuanzhu Biopharmaceutical Adds Employee Representative to Board as Executive Director Resigns
Premium
Company Announcements
Xuanzhu Biopharmaceutical Adds Employee Representative to Board as Executive Director Resigns
2M ago
2575
Xuanzhu Biopharmaceutical updates board and committee roles
Premium
Company Announcements
Xuanzhu Biopharmaceutical updates board and committee roles
2M ago
2575
Xuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
3M ago
2575
Xuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
3M ago
2575
Xuanzhu Biopharmaceutical Completes Full H-Share Circulation on HKEX
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Completes Full H-Share Circulation on HKEX
4M ago
2575
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
PremiumCompany Announcements
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
4M ago
2575
Xuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
PremiumCompany AnnouncementsXuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
4M ago
2575
Xuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
Premium
Company Announcements
Xuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
4M ago
2575
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori
Premium
Company Announcements
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori
4M ago
2575
Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan
5M ago
2575
Xuanzhu Biopharm Licenses Key Cancer Drugs to Boston Oncology for MENA Expansion
PremiumCompany Announcements
Xuanzhu Biopharm Licenses Key Cancer Drugs to Boston Oncology for MENA Expansion
5M ago
2575
Xuanzhu Biopharmaceutical Narrows Annual Loss on Surging Revenue and Deep Cost Cuts
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Narrows Annual Loss on Surging Revenue and Deep Cost Cuts
5M ago
2575
Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology
PremiumCompany Announcements
Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology
5M ago
2575
Xuanzhu Biopharm Completes Phase III Patient Enrollment for Anaprazole in Reflux Esophagitis
PremiumCompany AnnouncementsXuanzhu Biopharm Completes Phase III Patient Enrollment for Anaprazole in Reflux Esophagitis
5M ago
2575
Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision
Premium
Company Announcements
Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision
5M ago
2575
Xuanzhu Biopharm Added to Hong Kong Stock Connect, Boosting Access to Mainland Investors
Premium
Company Announcements
Xuanzhu Biopharm Added to Hong Kong Stock Connect, Boosting Access to Mainland Investors
6M ago
2575

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >